Antigenics Inc., of New York, said it received U.S. Patent Nos. 6,168,793; 6,162,436; 6,156,302; 6,143,299; 6,139,841 and 6,136,315. They cover heat shock proteins.
Aurora Biosciences Corp., of San Diego, said it received U.S. Patent No. 6,143,492 titled "Optical Molecular Sensors for Cytochrome P450 Activity." It covers high-throughput drug candidate screening technology.
Cerus Corp., of Concord, Calif., said it received U.S. Patent No. 6,171,777. It covers nucleic acid binding methods for inactivating viruses, bacteria and parasites in blood or blood components intended for transfusion.
Collateral Therapeutics Inc., of San Diego, said it received U.S. Patent No. 6,174,871 titled "Gene Therapies for Enhancing Cardiac Function." It covers angiogenic gene therapy methods for treating heart disease.
Cortex Pharmaceuticals Inc., of Irvine, Calif., said it received U.S. Patent No. 6,166,008 titled "Treatment of Schizophrenia with Ampakines and Neuroleptics." It covers the company's Ampakines and compounds that are positive modulators of the AMPA receptor.
Diversa Corp., of San Diego, said it received U.S. Patent No. 6,174,673. It covers high-throughput screening of gene libraries made from mixed populations of organisms using fluorescent detection.